159 related articles for article (PubMed ID: 29579318)
1. Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life.
Golan R; Bernstein AN; Gu X; Dinerman BF; Sedrakyan A; Hu JC
Cancer; 2018 May; 124(10):2212-2219. PubMed ID: 29579318
[TBL] [Abstract][Full Text] [Related]
2. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.
Dinan MA; Li Y; Zhang Y; Stewart SB; Curtis LH; George DJ; Reed SD
Clin Genitourin Cancer; 2016 Feb; 14(1):28-37.e2. PubMed ID: 26382223
[TBL] [Abstract][Full Text] [Related]
3. The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.
McDougall JA; Bansal A; Goulart BH; McCune JS; Karnopp A; Fedorenko C; Greenlee S; Valderrama A; Sullivan SD; Ramsey SD
Oncologist; 2016 Mar; 21(3):320-6. PubMed ID: 26865591
[TBL] [Abstract][Full Text] [Related]
4. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
5. Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study.
Abdollah F; Sammon JD; Majumder K; Reznor G; Gandaglia G; Sood A; Hevelone N; Kibel AS; Nguyen PL; Choueiri TK; Selvaggi KJ; Menon M; Trinh QD
J Natl Compr Canc Netw; 2015 Sep; 13(9):1131-8. PubMed ID: 26358797
[TBL] [Abstract][Full Text] [Related]
6. Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration.
Hung P; Hsu SH; Wang SY
Value Health; 2020 Jun; 23(6):697-704. PubMed ID: 32540226
[TBL] [Abstract][Full Text] [Related]
7. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
9. Hospice use and high-intensity care in men dying of prostate cancer.
Bergman J; Saigal CS; Lorenz KA; Hanley J; Miller DC; Gore JL; Litwin MS;
Arch Intern Med; 2011 Feb; 171(3):204-10. PubMed ID: 20937914
[TBL] [Abstract][Full Text] [Related]
10. Associations Among End-of-Life Discussions, Health-Care Utilization, and Costs in Persons With Advanced Cancer: A Systematic Review.
Starr LT; Ulrich CM; Corey KL; Meghani SH
Am J Hosp Palliat Care; 2019 Oct; 36(10):913-926. PubMed ID: 31072109
[TBL] [Abstract][Full Text] [Related]
11. Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs.
Falchook AD; Salloum RG; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):243-8. PubMed ID: 24321784
[TBL] [Abstract][Full Text] [Related]
12. Racial and ethnic variation in health resource use and cost for prostate cancer.
Jayadevappa R; Malkowicz SB; Chhatre S; Gallo J; Schwartz JS
BJU Int; 2010 Sep; 106(6):801-8. PubMed ID: 20151963
[TBL] [Abstract][Full Text] [Related]
13. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
14. Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease.
Li TT; Shore ND; Mehra M; Todd MB; Saadi R; Leblay G; Aggarwal J; Griffiths RI
Cancer; 2017 Sep; 123(18):3591-3601. PubMed ID: 28542732
[TBL] [Abstract][Full Text] [Related]
15. Racial differences in the cost of treating men with early-stage prostate cancer.
Brandeis J; Pashos CL; Henning JM; Litwin MS
J Am Geriatr Soc; 2001 Mar; 49(3):297-303. PubMed ID: 11300241
[TBL] [Abstract][Full Text] [Related]
16. End-of-life quality metrics among medicare decedents at minority-serving cancer centers: A retrospective study.
Wasp GT; Alam SS; Brooks GA; Khayal IS; Kapadia NS; Carmichael DQ; Austin AM; Barnato AE
Cancer Med; 2020 Mar; 9(5):1911-1921. PubMed ID: 31925998
[TBL] [Abstract][Full Text] [Related]
17. Palliative Transurethral Resection of the Prostate in Patients with Metastatic Prostate Cancer: A Prospective Study of 188 Patients.
Qu M; Zhu F; Chen H; Lian B; Jia Z; Shi Z; Li J; Wang Y; Sun Y; Gao X
J Endourol; 2019 Jul; 33(7):570-575. PubMed ID: 31025578
[No Abstract] [Full Text] [Related]
18. Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients Diagnosed With Stage IV Pancreatic Cancer.
Bao Y; Maciejewski RC; Garrido MM; Shah MA; Maciejewski PK; Prigerson HG
J Pain Symptom Manage; 2018 Apr; 55(4):1113-1121.e3. PubMed ID: 29241809
[TBL] [Abstract][Full Text] [Related]
19. The trajectory of patients who die from metastatic prostate cancer: a population-based study.
Collins A; Sundararajan V; Millar J; Burchell J; Le B; Krishnasamy M; McLachlan SA; Hudson P; Mileshkin L; Philip J
BJU Int; 2019 May; 123 Suppl 5():19-26. PubMed ID: 30371986
[TBL] [Abstract][Full Text] [Related]
20. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
